Abstract 559P
Background
Cancer patients often experience weight loss due to changes in metabolism and resting energy expenditure (REE) as well as low nutritional intake due to anorexia. Nutritional interventions and supplementation play an important role in preventing decreased intake and worsening nutritional status of cancer patient. One form of nutritional support for cancer patients is oral nutritional supplements (ONS). We investigated whether providing high calorie-protein ONS could support maintaining nutritional status and nutrient intake.
Methods
This was an open label randomized clinical trial (RCT) design conducted on gynaecology cancer patients who have not been or are undergoing therapy and were met the inclusion criteria. The study aimed to compare differences in nutritional status assessed from anthropometry (BW and BMI) and improvement in Hb levels. Subjects were divided into 2 groups, for the intervention group was given high calorie-protein ONS (Nutrican®) and dietary counselling, while the control group only received dietary counselling, intervention in both groups was conducted for 8 weeks. ONS was given 3 times a day as a morning snack; afternoon snack and evening snack (before bedtime).
Results
Between Mei 2023 until June 2024, a total of 78 patients had ECOG PS score 0-2 (35 subjects for intervention group, 43 subjects for control group) were able to complete the study. The analysis showed that the intervention group had significantly better changes (Δ) in mean weight (1.84±4.09 vs -0.77±2.57; P= 0.000) and body mass index (0.93±2.05 vs -0.48±1.03; P= 0.000) than the control group. The mean changes for Hb levels in both groups were not significantly different, but the number of patients who achieved normal Hb levels was higher in the intervention group (15 (42.9%) vs 9 (20.9%); P=0.037).
Conclusions
Results of this study concluded that providing high calorie-protein ONS accompanied by dietary counselling provided benefits in maintaining nutritional status parameters of bodyweight, body mass index and Hb.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.